The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | CD19 CAR T-cells for adults
David L. Porter, MD, of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults for CD19 positive hematological malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
